Results 101 to 110 of about 61,613 (221)

Eruptive Acral Melanocytic Lesions Associated With Capecitabine

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Eruptive nevi and lentigines have been reported to occur in the setting of immunosuppression, which may be medication‐induced. The associated histopathologic findings have not been well described in the literature. Herein, we report the case of a woman in her 60s who had been receiving chemotherapy treatment with capecitabine, a prodrug of 5 ...
Madison Smith, Annie Jin, Jonathan A. Miles, Rosalie Elenitsas, Danielle M. DeHoratius, Emily Y. Chu   +5 more
wiley   +1 more source

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Cancer Treatment and Research Communications
Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff   +13 more
doaj   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Transpapillary Placement of a Multihole Covered Metal Stent Using a 5.9‐Fr Delivery System Through a Forward‐viewing Endoscope in Malignant Biliary Obstruction With Type I Duodenal Stenosis

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Concurrent malignant biliary obstruction (MBO) and type I duodenal stenosis represent a technically demanding scenario, as luminal narrowing frequently precludes passage of a standard side‐viewing duodenoscope and limits conventional transpapillary drainage.
Kengo Matsumoto, Daisuke Kondo, Satoru Okabe, Naoto Osugi, Akira Doi, Masashi Yamamoto, Shiro Hayashi, Koji Fukui, Tsutomu Nishida   +8 more
wiley   +1 more source

Irinotecan [PDF]

Reactions Weekly, 2020
  +4 more sources

Rifaximin alleviates irinotecan-induced diarrhea in mice model

Annals of Medicine
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang, Huiyin Lan, Minghua Bai, Jinggang Chen, Shengkun Xu, Quanquan Sun, Qianping Chen, Wei Mao, Jin Jiang, Ji Zhu   +9 more
doaj   +1 more source

Gene–Dose Interaction in Low‐Dose Irinotecan: A Real‐World Cohort Study of the Association Between Adverse Effects and UGT1A1 Polymorphism

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 12, December 2026.
ABSTRACT Introduction Exposure to the toxic metabolite of irinotecan is higher in UGT1A1 poor metabolizers (PMs). It is uncertain if there is a higher risk for adverse effects in PMs receiving low‐dose irinotecan regimens (< 150 mg/m2). In this retrospective cohort study, we examined in a real‐world cohort the interaction between UGT1A1 polymorphism ...
Dafna Zukerman, Joul Hadad, Flavio Lejbkowicz, Ofra Barnett‐Griness, Naomi Gronich   +4 more
wiley   +1 more source

Renal function as a predictor of irinotecan-induced neutropenia

, 2008
Although approximately half of the administered dose of irinotecan is recovered in urine, scarce data are available on the association of renal function with irinotecan pharmacokinetics and toxicity.
de Jong, FA (Floris), Bol, Jessica, Gelder, Teun, Mathijssen, RHJ; id_orcid, Sparreboom, A, Wiemer, Erik; id_orcid, Verweij, Jaap   +6 more
core   +1 more source

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 6, Page 817-829, December 2026.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity

International Journal of Cancer, Volume 159, Issue 10, Page 2512-2524, 15 November 2026.
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron, Elena Peruzzi, Samantha Perfler, Marcella Montico, Riccardo Cecchin, Elena De Mattia, Michele Spina, Camilla Lisanti, Serena Corsetti, Luisa Foltran, Fabio Puglisi, Rossana Roncato, Erika Cecchin   +12 more
wiley   +1 more source